Two New Paths in Type 1 Diabetes: Slowing Disease and Restoring Insulin Production

Type 1 diabetes develops as an autoimmune disease, meaning the body's immune system mistakenly attacks the beta cells in the pancreas that produce insulin. What's significant for patients and families is that this attack doesn't happen overnight. Scientists can now detect the disease in progress, before a person shows any symptoms.

Researchers use a blood test to measure islet autoantibodies—proteins the immune system produces when it targets beta cells. When someone has at least two positive autoantibodies, they are classified in stage 1 of the disease. Some of these people then progress to stage 2, where blood sugar control begins to falter. Stage 3 is when Type 1 diabetes is clinically diagnosed and becomes obvious in symptoms and blood sugar levels.

Teplizumab is the first disease-modifying therapy approved for people at stage 2—those who have autoantibodies and early signs of declining beta cell function, but not yet full-blown Type 1 diabetes. It works by modulating the immune system to slow the attack on beta cells.

Clinical evidence shows that teplizumab delays the transition to stage 3 (clinically manifest Type 1 diabetes) by an average of 2 to 3 years. This delay matters: it gives people more time before they need insulin therapy and may allow the pancreas to preserve some of its own insulin-making capacity longer.

Beyond teplizumab, researchers are testing other immunomodulatory approaches in people newly diagnosed with Type 1 diabetes (stage 3). Early results suggest these therapies can slow the decline of remaining beta cell function—a process called beta cell preservation. However, none of these additional approaches are yet approved for clinical use.

The goal of these emerging therapies is to keep the pancreas working longer by protecting the beta cells that remain after initial diagnosis, reducing the insulin dose people need and potentially improving overall metabolic health.

A parallel research effort focuses on cell replacement therapy—using stem cells to generate new, functional beta cells that can produce insulin. This approach targets a different problem: instead of trying to stop the immune attack, it aims to restore the body's insulin-producing capacity by replacing the cells that have been lost.

Stem-cell-based beta cell therapies are currently in clinical testing in people with advanced Type 1 diabetes, particularly those with impaired awareness of low blood sugar (a complication that develops over time). While still investigational, these therapies represent a potential future strategy to restore independent insulin production.

The field of Type 1 diabetes treatment is expanding beyond insulin replacement alone. Two complementary strategies are taking shape: immunotherapies that can delay or slow disease progression, and cell therapies aimed at restoring the body's own insulin production. Neither is a cure, but together they represent meaningful progress in understanding and intervening in the disease process earlier and more effectively than ever before.

Source: Innere Medizin (Heidelberg, Germany). Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.